Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The Supreme Court refused to hear Merck’s arguments on a hepatitis C patent, so the previous ruling in Gilead’s favor stands.
Rates of liver complications were similar, but HIV-positive people had more non-liver cancers and non-liver-related deaths.
In a recent British Columbia study, 1 in 10 people who began treatment were lost to follow-up.
The assurance arrives as the pharma giant cuts off most emergency access to remdesivir, a potential COVID-19 treatment.
Though low, this figure is three times the rate of discontinuation seen in clinical trials.
There are a variety of hepatitis C treatments offered for all genotypes, with various stages of liver damage.
Often people are reluctant to start using a hep C medication because they are concerned about the possible side effects during treatment.
Here is a fantastic story from Jonathan Nakamoto in the USA who treated and cured his hepatitis C with generic Harvoni from India in 2016.
There has been a lot of discussion about the side effects of Harvoni and other hepatitis C treatments with direct acting antivirals.
A U.S. appeals court upheld a judge’s previous decision to throw out a record-setting 2016 verdict in Merck’s favor.
Ninety-seven percent of the children were cured of hepatitis C.
The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.
September 4, 2019, the U.S. FDA released their recent approval of new dosage forms of Sovaldi and Harvoni for children 3 to 12 years of age.
The presence of less studied HCV genotypes may compromise cure rates.
Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.
Researchers compared outcomes among those with and without hep C before and after Sovaldi was approved in late 2013.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.